WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 207088
CAS#: 1978336-61-6
Description: GB1107 is a potent, selective, orally active galectin-3 inhibitor with Kd of 37 nM. GB1107 Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade.
MedKoo Cat#: 207088
Name: GB1107
CAS#: 1978336-61-6
Chemical Formula: C20H16Cl2F3N3O4S
Exact Mass: 521.0191
Molecular Weight: 522.3202
Elemental Analysis: C, 45.99; H, 3.09; Cl, 13.57; F, 10.91; N, 8.05; O, 12.25; S, 6.14
Synonym: GB1107; GB-1107; GB 1107;
IUPAC/Chemical Name: 3,4-dichlorophenyl 3-deoxy-3-[4(3,4,5-trifluorophenyl)-1H-1,2,3- triazol-1-yl]-1-thio-α-D-galactopyranoside
InChi Key: CSGJIUAIYDKFPC-DABHTEOTSA-N
InChi Code: InChI=1S/C20H16Cl2F3N3O4S/c21-10-2-1-9(5-11(10)22)33-20-19(31)17(18(30)15(7-29)32-20)28-6-14(26-27-28)8-3-12(23)16(25)13(24)4-8/h1-6,15,17-20,29-31H,7H2/t15-,17+,18+,19-,20-/m1/s1
SMILES Code: O[C@H]([C@@H](N1N=NC(C2=CC(F)=C(F)C(F)=C2)=C1)[C@H]([C@@H](CO)O3)O)[C@H]3SC4=CC=C(Cl)C(Cl)=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | GB1107 is a potent, selective, orally active inhibitor of Galectin-3 (Gal-3) with a Kd of 37 nM for human Galectin-3. |
| In vitro activity: | Additionally, the exposure of LNCaP cells to 2-PMPA showed a dose-dependent effect with ~52% cell death at 200 nM (p < 0.001) and no quantifiable cell death in LNCaP-KD and PC-3 cells (Figure 4B). However, GB1107 by itself showed dose-dependent cytotoxic effect on all cell lines with ~60% cell death at 10 μM, the highest dose (Figure 4C). Reference: Cancers (Basel). 2022 May 30;14(11):2704. https://pubmed.ncbi.nlm.nih.gov/35681683/ |
| In vivo activity: | Oral administration of a novel small molecule galectin-3 inhibitor GB1107 reduced human and mouse lung adenocarcinoma growth and blocked metastasis in the syngeneic model. Treatment with GB1107 increased tumor M1 macrophage polarization and CD8+ T-cell infiltration. Moreover, GB1107 potentiated the effects of a PD-L1 immune checkpoint inhibitor to increase expression of cytotoxic (IFNγ, granzyme B, perforin-1, Fas ligand) and apoptotic (cleaved caspase-3) effector molecules. Reference: Cancer Res. 2019 Apr 1;79(7):1480-1492. https://pubmed.ncbi.nlm.nih.gov/30674531/ |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 50.0 | 95.73 |
The following data is based on the product molecular weight 522.3202 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Sharma S, Cwiklinski K, Sykes DE, Mahajan SD, Chevli K, Schwartz SA, Aalinkeel R. Use of Glycoproteins-Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer. Cancers (Basel). 2022 May 30;14(11):2704. doi: 10.3390/cancers14112704. PMID: 35681683; PMCID: PMC9179331. 2. Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A, Gravelle L, Tantawi S, Schambye H, Sethi T, MacKinnon AC. An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade. Cancer Res. 2019 Apr 1;79(7):1480-1492. doi: 10.1158/0008-5472.CAN-18-2244. Epub 2019 Jan 23. PMID: 30674531. |
| In vitro protocol: | 1. Sharma S, Cwiklinski K, Sykes DE, Mahajan SD, Chevli K, Schwartz SA, Aalinkeel R. Use of Glycoproteins-Prostate-Specific Membrane Antigen and Galectin-3 as Primary Tumor Markers and Therapeutic Targets in the Management of Metastatic Prostate Cancer. Cancers (Basel). 2022 May 30;14(11):2704. doi: 10.3390/cancers14112704. PMID: 35681683; PMCID: PMC9179331. |
| In vivo protocol: | 1. Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A, Gravelle L, Tantawi S, Schambye H, Sethi T, MacKinnon AC. An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 Blockade. Cancer Res. 2019 Apr 1;79(7):1480-1492. doi: 10.1158/0008-5472.CAN-18-2244. Epub 2019 Jan 23. PMID: 30674531. |
1: Vuong L, Kouverianou E, Rooney CM, McHugh BJ, Howie SEM, Gregory CD, Forbes
SJ, Henderson NC, Zetterberg FR, Nilsson UJ, Leffler H, Ford P, Pedersen A,
Gravelle L, Tantawi S, Schambye H, Sethi T, MacKinnon AC. An Orally Active
Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response
to PD-L1 Blockade. Cancer Res. 2019 Apr 1;79(7):1480-1492. doi:
10.1158/0008-5472.CAN-18-2244. Epub 2019 Jan 23. PubMed PMID: 30674531.
